NextGenAMR — a product by Vanguard Biotech Systems
Reviewable genomic evidence for antimicrobial resistance workflows.
NextGenAMR is a genomic antimicrobial-resistance intelligence platform in development, designed to turn bacterial whole-genome sequencing into probabilities of resistance for the antibiotics in its predictive panel, with explicit uncertainty or an abstention, and provenance for every step — not a clinical diagnosis.
In development · Not for clinical use
In development. The E. coli engine is being built and will be evaluated internally under a pre-specified protocol. An independent external validation protocol has been drafted. No performance results have been published. Not for clinical use.
In one look
- What goes in (by design)
- Input (by design) — Whole-genome sequencing reads (paired-end FASTQ) of a single cultured isolate. Not primary samples, not metagenomics.
- What it is designed to do
- NextGenAMR is designed to take a bacterial genome within its scope through a controlled workflow, organise resistance-related signals, keep the traceability of how they were obtained and generate structured outputs for a professional to review together with other tests and the relevant context.
- What would come out
- Output (by design) — For each antibiotic in the predictive panel, a probability of resistance with explicit uncertainty — or an abstention. Never a categorical S/I/R result.
- Who reviews it
- NextGenAMR is not presented as an autonomous diagnostic system; it is designed to organise genomic evidence and generate outputs for professional review.
- What state it is in
- In development. The E. coli engine is being built and will be evaluated internally under a pre-specified protocol. An independent external validation protocol has been drafted. No performance results have been published. Not for clinical use.
Scope today
- First species
- Escherichia coli — In development
- Candidate first panel
- Ampicillin, Ciprofloxacin, Cefotaxime, Ceftazidime, Gentamicin — subject to evaluation
- Next species
- Klebsiella pneumoniae — Planned
NextGenAMR's first species is Escherichia coli, in development, with a candidate first panel of ampicillin, ciprofloxacin, cefotaxime, ceftazidime and gentamicin, subject to evaluation. Carbapenems: genotypic evidence only, with no model probability. No species is yet released for use.
Built for many species, one at a time. NextGenAMR's architecture is designed to work with a separate profile for each species — its own panel, quality rules, features and models — and no species inherits evidence from another. Being designed for several species is not the same as having evidence for them: evidence is generated and assessed separately for each one. Escherichia coli is the only species in development; Klebsiella pneumoniae is the next planned species. No dates are committed.
Scope updated 2026-10-21
What exists today
One status per row: Built (internal R&D) · In development · Designed · Planned · Not claimed.
- Processing pipeline, quality control, species checks, mechanism detection and per-batch provenanceBuilt (internal R&D)
- Structured reportingIn development
- E. coli resistance modelsIn developmentUnder a pre-specified protocol
- Internal evaluation (R&D)PlannedNot a basis for performance claims
- Independent external validationPlannedProtocol drafted; partner laboratories sought
- Clinical use / regulatory statusNot claimedNone claimed
What a result is designed to contain
What a NextGenAMR result is designed to contain: a quality-control verdict with reason codes, species confirmation, the resistance mechanisms detected, a probability of resistance with its uncertainty for each antibiotic in the predictive panel — or an abstention with its reason — and the provenance of every step. No results are shown on this website.
How it works in detail →What it is designed to help with
- Consolidating a fragmented, multi-step workflow into one governed process.
- Reproducibility, provenance and version control.
- Normalised, consistent outputs designed for structured review.
- Auditability of how each output was produced.
It does not promise faster treatment, reduced mortality, cost savings or lower workload — those require approved measurements that do not exist.
What NextGenAMR does not do
- It is in development and is not available for use.
- Does not replace phenotypic AST (antibiogram).
- Does not make autonomous clinical decisions.
- Does not prescribe or select treatments.
- Absence of a detected marker does not guarantee susceptibility.
- Do not send samples, sequences, files, identifiers or patient data through this website.
NextGenAMR is in development and is not intended for clinical use. It has no authorisation or declaration of conformity for clinical diagnostic use: no CE marking under the EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) and no FDA marketing authorisation. No ISO 13485 quality-management certification is claimed.
Evaluation and validation
Programme status: engine in development; internal evaluation criteria pre-specified; external validation protocol drafted.
No performance results have been published for NextGenAMR's current evidence-grade engine.
Evidence and programme status →Questions institutions ask
Does it replace AST?
NextGenAMR does not replace phenotypic antimicrobial susceptibility testing (AST). Genomic outputs must be interpreted together with AST, microbiological context and applicable procedures.
Have performance results been published?
No performance results have been published for NextGenAMR's current evidence-grade engine.
Is it certified or intended for clinical use?
NextGenAMR is in development and is not intended for clinical use. It has no authorisation or declaration of conformity for clinical diagnostic use: no CE marking under the EU In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746) and no FDA marketing authorisation. No ISO 13485 quality-management certification is claimed.
How would a validation collaboration work?
We welcome conversations with clinical, research and surveillance institutions about future validation collaborations.